SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-17-001229
Filing Date
2017-01-06
Accepted
2017-01-06 17:11:26
Documents
9
Period of Report
2017-01-06
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K a17-1304_48k.htm 8-K 43286
2 EX-1.1 a17-1304_4ex1d1.htm EX-1.1 306649
3 EX-4.1 a17-1304_4ex4d1.htm EX-4.1 78659
4 EX-5.1 a17-1304_4ex5d1.htm EX-5.1 17335
5 EX-99.1 a17-1304_4ex99d1.htm EX-99.1 10821
6 EX-99.2 a17-1304_4ex99d2.htm EX-99.2 12319
7 GRAPHIC g13044kii001.jpg GRAPHIC 2760
8 GRAPHIC g13044moi001.jpg GRAPHIC 5216
9 GRAPHIC g13044mmi001.gif GRAPHIC 7642
  Complete submission text file 0001104659-17-001229.txt   492127
Mailing Address 9393 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 9393 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121 858-332-3410
Mirati Therapeutics, Inc. (Filer) CIK: 0001576263 (see all company filings)

IRS No.: 462693615 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35921 | Film No.: 17515014
SIC: 2834 Pharmaceutical Preparations